Alkem Laboratories on Friday said it has not received any observations from the United States Food and Drug Administration for its Daman facility. The USFDA had conducted the inspection from January 14 to 18. It may be recalled that in response to the detailed corrective and preventive action (in December 2018) for the company’s St Louis plant, the USFDA had closed the inspection report. In March 2018, the USFDA had issued Form 483, containing just one observation.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.